Cargando…

HGG-06. CHARACTERIZATION OF THE EFFECT OF THE ORAL IRON-MIMETIC GALLIUM MALTOLATE ON PEDIATRIC GLIOBLASTOMA GROWTH IN VIVO

BACKGROUND: Glioblastoma (GBM) is a highly aggressive CNS tumor that is associated with poor outcome. This dire prognosis is due in part to its poor response to the limited treatment options available. Iron and iron proteins play a key role in the growth of brain tumors, with our published studies s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Gizawiy, Mona M, Wujek, Robert T, Zoss, Casey J, Tanaka, Ryuma, Mirza, Shama P, Chitambar, Christopher R, Schmainda, Kathleen M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260053/ http://dx.doi.org/10.1093/neuonc/noad073.155

Ejemplares similares

ATRT-03. THE ORAL IRON-MIMETIC GALLIUM MALTOLATE INHIBITS ATRT IN VIVO – IMAGING AND HISTOLOGICAL CHARACTERIZATION
por: Al-Gizawiy, Mona, et al.
Publicado: (2023)

HGG-24. A NOVEL ONCOGENIC ROLE FOR MENIN IN GLIOMA
por: Yang, Yanhong, et al.
Publicado: (2023)

HGG-02. METABOLIC TARGETING OF HIGH-GRADE GLIOMAS WITH MTAP LOSS
por: Subramaniam, Bavani, et al.
Publicado: (2023)

HGG-04. INFANTILE HIGH GRADE GLIOMA: HONG KONG EXPERIENCE
por: Ning Lau, Sarah Sau, et al.
Publicado: (2023)

HGG-12. INFANT HEMISPHERIC GLIOMA: CLINICAL AND MOLECULAR CHARACTERISTICS AND RESULTS OF TARGETED THERAPY
por: Papusha, Ludmila, et al.
Publicado: (2023)

HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
por: Hu, Wanming, et al.
Publicado: (2023)

HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI
por: Crampsie, Shauna, et al.
Publicado: (2023)

HGG-15. HIGH-GRADE GLIOMAS OCCURRING IN TEENAGERS AND YOUNG ADULT PATIENTS COMPRISE NOVEL MOLECULAR SUBGROUPS
por: Clarke, Matthew, et al.
Publicado: (2023)

HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES
por: Yenidogan, Irem, et al.
Publicado: (2023)

HGG-21. ABERRANT SPLICING OF CLK1 IN PEDIATRIC HIGH-GRADE GLIOMAS DISRUPTS KEY ONCOGENIC TRANSCRIPTIONAL PROGRAMS
por: Naqvi, Ammar, et al.
Publicado: (2023)

HGG-07. OVEREXPRESSION OF A PLAG-FAMILY TRANSCRIPTION FACTOR DURING MURINE BRAIN DEVELOPMENT CAUSES BRAIN TUMOR FORMATION
por: Vaillant, Jan, et al.
Publicado: (2023)

HGG-14. RAS PATHWAY MEDIATED REGULATION OF HISTONE METHYLTRANSFERASE AND TUMOR SUPPRESSOR SETD2 IN PEDIATRIC HIGH GRADE GLIOMA
por: Liou, Angela, et al.
Publicado: (2023)

HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
por: Postlmayr, Andreas, et al.
Publicado: (2023)

HGG-20. NOVEL PAEDIATRIC CASE OF A SPINAL HIGH-GRADE ASTROCYTOMA WITH PILOID FEATURES IN A PATIENT WITH NOONAN SYNDROME
por: Staunton, Jordan, et al.
Publicado: (2023)

HGG-23. DECIPHERING THE RELATIONSHIP OF MICROSATELLITE-INSTABILITY AND MUTATIONAL BURDEN IN HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONALLY IMPAIRED DNA DAMAGE RESPONSE
por: Blattner-Johnson, Mirjam, et al.
Publicado: (2023)

HGG-03. HIGH-GRADE GLIOMA IN YOUNG CHILDREN IS HISTOLOGICALLY, MOLECULARLY, AND CLINICALLY DIVERSE—RESULTS FROM THE SJYC07 TRIAL AND INSTITUTIONAL EXPERIENCE
por: Chiang, Jason, et al.
Publicado: (2023)

HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
por: Johnson, Theodore S, et al.
Publicado: (2023)

HGG-27. THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A REPORT FROM THE IRRDC AND THE GLIOMA TASK FORCE
por: Negm, Logine, et al.
Publicado: (2023)

HGG-22. PROGNOSTIC FACTORS FOR PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH NON-DIPG GRADE 4 GLIOMAS: A CONTEMPORARY POOLED INSTITUTIONAL EXPERIENCE
por: Matsui, Jennifer, et al.
Publicado: (2023)

HGG-11. APPLICATION OF SHUNT IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA COMPLICATED WITH HYDROCEPHALUS: A 10-YEAR EXPERIENCE FROM A SINGLE CENTER
por: Cai, Linbo, et al.
Publicado: (2023)

HGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES
por: Nussbaumer, Gunther, et al.
Publicado: (2023)

HGG-25. TARGETED DRUGS SYNERGIZE WITH DOUBLE ALKYLATOR THERAPY IN H3.3 G34R/V PEDIATRIC HIGH-GRADE GLIOMA
por: Haase, Rebecca, et al.
Publicado: (2023)

HGG-26. GENOMIC AND IMMUNE ANALYSIS OF PRIMARY REPLICATION-REPAIR DEFICIENT (RRD) GLIOMAS REVEALS THREE SUBGROUPS WITH DISTINCT DRIVERS AND RESPONSE TO IMMUNOTHERAPY: AN IRRDC REPORT
por: Fernandez, Nicholas R, et al.
Publicado: (2023)

HGG-10. A SAFETY AND EFFICACY STUDY OF NOVOTTF-100A FOR PEDIATRIC HIGH-GRADE GLIOMA: RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE FIRST THREE CASES
por: Makimoto, Atsushi, et al.
Publicado: (2023)

HGG-05. PERTURBING GABAERGIC NEURONAL LINEAGE IN DIFFUSE HEMISPHERIC GLIOMA, H3G34-MUTANT, HIGHLIGHTS CDK6 AS A CLINICALLY ACTIONABLE TARGET
por: Liu, Ilon, et al.
Publicado: (2023)

HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION
por: Mayr, Lisa, et al.
Publicado: (2023)

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS
por: DeSisto, John, et al.
Publicado: (2023)

TIPS-03 A PHASE 1 STUDY OF GALLIUM MALTOLATE (GAM) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
por: Connelly, Jennifer, et al.
Publicado: (2023)

HGG-06. REMARKABLE RESPONSE TO BRAF INHIBITOR IN AN INFANT WITH DISSEMINATED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT)
por: Aung, Le Le
Publicado: (2020)

HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA
por: Liu, Ilon, et al.
Publicado: (2021)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study.
por: Perwein, Thomas, et al.
Publicado: (2022)

HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe
por: Giraud, Géraldine, et al.
Publicado: (2022)

HGG-31. UNIQUE BIOLOGICAL CHARACTERISTICS OF RADIATION-INDUCED GLIOMAS
por: Váňová, Kateřina, et al.
Publicado: (2020)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

HGG-21. MALIGNANT SYNAPTIC PLASTICITY IN PEDIATRIC HIGH-GRADE GLIOMAS
por: Taylor, Kathryn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8ioblbe1lueo9eh3bo7c2orrj